Novavax COVID-19 vaccine discussed by disease expert
Novavax researchers have created a vaccine candidate now on track to join the others currently in operation. Their vaccine, named NVX-CoV2373, returned effectivity rates of 89.3 percent, a near match for its competitors. Doses will eventually make their way through vaccination programmes around the world but needs approval first.
Which country made the Novavax vaccine?
Much like the other coronavirus candidates, international cooperation backed the Novavax vaccine.
The vaccine development company has headquarters in Maryland, on the US east coast.
The company has additional facilities in Sweden but chose to manufacture “the bulk” of its jabs in the UK.
We will use your email address only for sending you newsletters. Please see our Privacy Notice for details of your data protection rights.
Novavax enlisted FUJIFILM Diosynth Biotechnologies, another international firm with a base in Stockton-on-Tees.
They created the first batch of NVX-CoV2373 in Billingham.
The Government said its location would allow vaccine authorities to distribute it with ease.
But they can’t use it just yet, as it requires approval first.
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for approving vaccines in the UK.
The organisation has approved three other jabs in the UK so far, from Pfizer, AstraZeneca and Moderna.
They have not indicated how long it will take to approve the Novavax vaccine.
But when they do, the Vaccine Taskforce will have 60 million doses.
DON’T MISS
Beware of these scarily convincing Covid-19 vaccine emails – ANALYSIS
BBC Breakfast’s Boris Johnson blunder sparks frenzy ‘Tough lockdown’ – VIDEO
EU to ban exporting vaccines TODAY – top eurocrat issues legal threat – INSIGHT
They will become part of the UK’s vaccine strategy and have already proven effective against Covid variants.
Research found effectivity rates held when phase three participants included 50 percent of people with Covid cases “attributable to the UK variant”.
Rates also remained during a phase 2b South Africa trial, where over 90 percent of people had cases attributable to the other local variant.
Experts have hailed the results, among them Clive Dix, chair of the UK Vaccine Taskforce.
In a statement, Mr Dix said the Novavax jab would benefit people around the world.
He said: “These are spectacular results, and we are very pleased to have helped Novavax with the development of this vaccine.
“The efficacy shown against the emerging variants is also extremely encouraging.
“This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus.”
Source: Read Full Article